Sapphire Bioscience Holding ApS: Financial statements 2018
CVR: 38599917
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
Sapphire Bioscience Holding ApS (CVR 38599917) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK -61,625 and a net result of DKK 40,003,676. Equity in the 2018 report amounted to DKK 98,450,069. The solvency ratio was 99.9%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -61,625
- Profit/Loss
- DKK 40,003,676
- Equity
- DKK 98,450,069
- Total Assets
- DKK 98,591,390
- Employees
- 1
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
Sapphire Bioscience Holding ApS has published its interim report for the period April 27, 2017 – December 31, 2017.
About Sapphire Bioscience Holding ApS
Sapphire Bioscience Holding ApS is a Danish company of the type Anpartsselskab based in Ballerup, founded in 2017. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Michel Krall Jürgens. The board consists of Harald Høegh (chair), Eirik Lauglo, Gustaf Peter Reinhold von Ehrenheim and Peter Max. The company is owned by TTJ Invest Holding ApS and Vind Industry AS. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of DKK -112,000 and a net result of DKK 3,266,000 compared with DKK 38,793,000 the year before. Equity in the 2025 report amounted to DKK 148,277,000.